XORTX Therapeutics Inc(XRTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.74 | Insider Own | 7.84% | Shs Outstand | 1.7M | Perf Week | -8.6% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 1.7M | Perf Month | -27.29% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 2.23% | Short Float | 4.6% | Perf Quarter | -21.66% |
| Income | -0.00B | P/S | - | EPS this Y | - | Inst Trans | 2.39% | Short Ratio | 0.34 | Perf Half Y | -11.23% |
| Sales | 0.00B | P/B | 0.53 | EPS next 5Y | - | ROA | -83.78% | Short Interest | 0.08M | Perf YTD | -39.5% |
| Book/sh | 3.18 | P/C | 3.12 | EPS past 3/5Y | 51.52% 15.39% | ROE | -99.24% | 52W High | -75.89% ($7.05) | Perf Year | -57.29% |
| Cash/sh | 0.54 | P/FCF | - | Sales past 3/5Y | - | ROIC | -67.93% | 52W Low | 6.91% ($1.59) | Perf 3Y | -93.7% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -1.91% | Gross Margin | - | Volatility(W/M) | 5.46% 11.92% | Perf 5Y | -99.11% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.21 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.59 | EPS Q/Q | -10.34% | Profit Margin | - | RSI (14) | 40.22 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.59 | Sales Q/Q | - | SMA20 | -14.18% ($1.98) | Beta | 0.57 | Target Price | $70 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/17 | SMA50 | -17.71% ($2.07) | Rel Volume | 0.32 | Prev Close | $1.71 |
| Employees | 3 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -26.26% ($2.31) | Avg Volume(3M) | 0.22M | Price | $1.7 |
| IPO | 2018/11/28 | Option/Short | No/Yes | Trades | 148 | Volume | 71,431 | Change | -0.58% |
🩺 This is a Canada-based micro-cap clinical-stage biotech developing treatments for chronic kidney disease and gout, targeting uric acid metabolism. Its lead programs are XORLO™ (XRx-026), a gout treatment based on the xanthine oxidase inhibitor oxypurinol, and XRx-008, a treatment for autosomal dominant polycystic kidney disease (ADPKD).
Over the past 1 year, on the lower side
76% below its 1-year high.
Traded less than usual That is 32% of its average volume.
XRTX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.1%. The S&P 500 did +76% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 2.2%.
Tap to view numbers
It ranks #572 of 592 in the industry
Based on market cap of $3M.
REVB#570 Revelation Biosciences Inc $3M PER - 
BRTX#571 BioRestorative Therapies Inc $3M PER - XRTX#572 XORTX Therapeutics Inc $3M PER - 
VRAX#573 Virax Biolabs Group Ltd $3M PER - 
ELAB#574 PMGC Holdings Inc $3M PER - 
FAQ
What kind of company is XRTX?
XRTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of XRTX?
The market cap of XRTX is approximately $3M, ranking 5,787 within its sector.
What is the 52-week high and low for XRTX?
XRTX has recorded a 52-week high of $7.05 and a low of $1.59.
